Introduction {#s1}
============

Atherosclerosis is a strong risk factor for cardiovascular and cerebrovascular diseases, which are the leading causes of death and disability worldwide ([@B1]), and have become an important public health concern in China ([@B2]). Although individuals with atherosclerosis are usually without symptoms in the early stages, atherosclerosis can progress at their young age and throughout the lifetime. Atherosclerosis involves the progressive narrowing of the vessel\'s lumens, which may lead to acute cardiac ischemia, myocardial infarction, or stroke. The carotid intima--media thickness (CIMT), measured by a carotid ultrasound, has been used as a surrogate indicator for atherosclerosis. However, CIMT provided less clear evidence for atherosclerotic infiltration in the vessel wall than a significant carotid atherosclerotic plaque (CAP) does ([@B3]). Several studies have demonstrated that, compared to the mean IMT, CAP could predict the occurrence of cardiovascular and cerebrovascular diseases more accurately.

Recently, it has been recognized that atherogenesis is not only a passive injury with infiltration of lipids but is also an active inflammatory process. The relationship of the white blood cell (WBC) count with inflammation in various diseases has been investigated ([@B4]--[@B6]). WBCs comprised the subtypes of neutrophils, lymphocytes, monocytes, eosinophils, and basophils, each of which plays a distinct inflammatory and immunologic role and may contribute differently to the development of atherosclerosis ([@B7]). Several studies have confirmed the association of the WBC count with the risk of cardiac cerebral disease ([@B8], [@B9]). Recruitment of leukocytes to the vascular endothelium wall represents an early stage in the initiation and development of atherosclerosis ([@B10]). Although increased leukocytes have been reported to correlate with CAP, the associations of the WBC subgroups with CAPs have not been compared ([@B11]). As the WBC count is an inexpensive and widely used test, we conducted the current study to more fully explore the associations between WBCs and the presence, severity, and types of CAPs.

Methods {#s2}
=======

Design and Study Population
---------------------------

This cross-sectional study included 3,569 healthy Chinese subjects (2,464 men and 1,105 women) aged 18--97 years, and the associations of the total WBC and WBC subtypes with CAPs were investigated. All subjects were recruited through a general health screening programme between January 2016 and December 2018 in Zhengzhou, China. Individuals were excluded for the following reasons: (i) a history of cardiovascular disease, including coronary heart disease, stroke, thromboembolic disease, congestive heart failure, or peripheral arterial disease; (ii) cancer; (iii) infectious disease; (iv) serious liver or renal disorders; and (v) currently on medication. The current study was approved by the Research Ethical Committee of the First Affiliated Hospital of Zhengzhou University, and written informed consent was obtained from each participant at the time of enrollment.

Parameter Measurements
----------------------

Weight and height were measured using an autoanthropometer, and body mass index (BMI) was calculated with the formula: weight in kilograms divided by height in meter squared. Blood pressure was measured by an electronic sphygmomanometer after the subjects had been sitting in a relaxed position for 10 min. Data on smoking, drinking, and history of diseases were collected using a standard physician-administered questionnaire. Smokers and drinkers were defined as participants who smoked one or more cigarettes per day and drank alcohol once or more a week for at least 6 months, respectively.

Fasting peripheral vein blood (5 ml) was drawn in EDTA-anticoagulant tubes. After centrifugation at 1,500 × g for 15 min at 4°C, plasma and blood cells were separated within 2 h. The total WBC and WBC subtype (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) counts and their percentages were assayed automatically by a blood cell counter (Beckman Coulter, Miami, FL, USA). Standard quality control procedures were followed in the laboratory. The plasma levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), glucose, and uric acid were measured using a fully automatic analyzer (Roche Molecular Systems, Inc., Basel, Switzerland) module Cobas 8000 (C701/C702/C502). The coefficient of variation for repeated measurements on the blood samples was maintained at a level of 2.5%.

Atherosclerosis Assessment
--------------------------

The presence of CAPs was measured bilaterally by B-mode ultrasound using an Aplio 300 ultrasound system (Toshiba Medical Systems, Tokyo, Japan). Measurements were taken in the far wall of the common carotid artery (CCA), the internal carotid artery (ICA), and the external carotid artery (ECA). When the subjects have lain in a supine position, the image of the extracranial carotid arteries were acquired in the longitudinal (anterior, lateral, and posterior views) and transverse planes. CAP was defined as a local protrusion of at least 0.5 mm, a 50% local thickening of IMT, or a CIMT \>1.5 mm ([@B12]).

When a plaque was imaged, the view of the thickest part of the plaque was frozen and an electronic cursor was used to measure the intimal--medial wall thickness (including the plaque), recording it as the maximal internal carotid plaque thickness (MICPT) for that artery. When no plaque was identified, the MICPT was recorded as zero ([@B13]). The plaque score was thereafter calculated by summing the measurements of plaque thickness in both carotid arteries ([@B14]).

According to ultrasound imaging, plaques were classified into three types: echolucent (low grayscale median, lipid-rich), echogenic (high grayscale median, mostly occupied by calcified areas), or heterogeneous (mixed echolucent and echogenic) ([@B15]). A plaque was classified as a polytype when more than one composition was present. All CAP measurements were conducted by the same senior physician using B-mode ultrasound, and strict quality control procedures were followed during image acquisition.

Statistical Analyses
--------------------

The data are presented as means with standard deviations (SDs) for the continuous variables and count with frequencies for the categorical variables. Student\'s *t*-test and Pearson\'s chi-square test were conducted, as appropriate. Pearson\'s correlation analysis was used to assess the relationship between blood cell counts and lipid profiles.

The study participants were divided into quartiles according to their total and differential WBC counts and by gender. Binary logistical regression models were applied to estimate the association of total and differential WBC counts with the presence of CAPs. Three models were developed: model 1, adjusted for age and BMI; model 2, further adjusted for fasting plasma lipid profiles, fasting plasma glucose, systolic blood pressure (SBP), diastolic blood pressure (DBP), and uric acid; and model 3, further adjusted for drinker and smoker (only for men). The potential non-linear associations of the blood cell counts with the presence of CAPs were assessed by restricted cubic spline with three knots.

The study participants were also divided into quartiles according to their MICPT and plaque scores. The lowest two quartiles (Q1 and Q2) were combined into one category (Q1--Q2); the MICPT and plaque scores of all participants in these quartiles were recorded as zero. Analysis of covariance (ANCOVA) was adopted to compare the mean total and differential WBC counts according to the sum and the composition of CAPs and the quartiles of MICPT and plaque score. The same covariates were adjusted for the ANCOVA as those in the regression analysis. Pairwise comparisons were performed using the Bonferroni test.

The analyses were performed with SPSS 13.0 (SPSS, Inc., Chicago, USA) and R 3.6.0 (R Core Team, Vienna, Austria). Two-sided *P* \< 0.05 indicated statistical significance.

Results {#s3}
=======

Baseline Characteristics
------------------------

Of the 3,569 subjects, 331 were excluded in accordance with the exclusion criteria and due to incomplete data. Thus, a total of 3,238 participants were included in the analysis. [Table 1](#T1){ref-type="table"} summarizes the baseline characteristics of the study participants by gender. The 2,249 men and 989 women had mean ages of 50.6 ± 10.8 and 51.2 ± 10.8 years, respectively. Total WBC and most of the differential WBC counts were higher in men than in women (*P* ≤ 0.010). The percentages of subjects with plaques in any carotid artery, CCA, ICA, or ECA were also higher in men than in women (*P* \< 0.001): 49.6, 46.6, 14.2, and 3.7% for men and 31.9, 29.0, 6.5, and 1.4% for women, respectively. Sex differences were also found in the MICPT, plaque score, and the count and composition of CAPs (*P* \< 0.001). Pearson\'s analysis revealed that the total WBC and neutrophil counts were significantly associated with TG and HDL-c (*P* \< 0.05), but not TC or LDL-c, and the monocyte count was only significantly associated with TG (*P* \< 0.05; [Figure S1](#SM1){ref-type="supplementary-material"}).

###### 

Characteristics of the study participants.

                                **Men**   **Women**   ***P***                               
  ----------------------------- --------- ----------- --------- --------- ------- --------- ---------
  Age (years)                   50.6      10.8        2,249     51.2      10.8    989       0.154
  Height (cm)                   172.5     5.7         1,948     160.7     5.9     824       \<0.001
  Weight (kg)                   77.8      10.0        1,949     62.1      8.8     826       \<0.001
  BMI (kg/m^2^)                 26.1      2.9         1,948     24.0      3.2     824       \<0.001
  SBP (mmHg)                    132.6     17.7        1,934     127.3     19.8    808       \<0.001
  DBP (mmHg)                    82.2      12.9        1,933     74.4      12.8    808       \<0.001
  Plasma glucose (mmol/L)       5.40      1.62        2,147     5.16      1.15    925       \<0.001
  Uric acid (mmol/L)            348.9     91.5        2,197     253.4     75.2    975       \<0.001
  TC (mmol/L)                   4.67      1.07        2,126     4.73      1.05    959       0.158
  TG (mmol/L)                   2.05      4.57        2,146     1.42      0.96    961       \<0.001
  HDLc (mmol/L)                 1.30      0.47        2,143     1.50      0.46    953       \<0.001
  LDLc (mmol/L)                 2.95      0.87        2,101     2.99      0.81    931       0.212
  Total WBC Count (× 10^9^/L)   6.44      1.68        2,236     5.82      1.55    987       \<0.001
  Neutrophils (× 10^9^/L)       3.79      1.53        2,248     3.38      1.16    989       \<0.001
  Neutrophils (%)               57.7      7.74        2,245     57.5      7.90    988       0.555
  Lymphocytes (× 10^9^/L)       2.04      0.58        2,247     1.90      0.57    986       \<0.001
  Lymphocytes (%)               32.0      7.07        2,221     33.3      7.16    981       \<0.001
  Monocytes (× 10^9^/L)         0.46      0.24        2,243     0.38      0.25    988       \<0.001
  Monocytes (%)                 7.09      1.83        2,245     6.49      1.63    989       \<0.001
  Eosinophils (× 10^9^/L)       0.43      1.17        2,247     0.33      0.86    988       0.01
  Eosinophils (%)               2.34      2.25        2,248     1.94      1.86    988       \<0.001
  Basophils (× 10^9^/L)         0.05      0.08        2,246     0.05      0.08    989       0.286
  Basophils (%)                 0.52      0.25        2,248     0.53      0.22    989       0.302
  MICPT (mm)                    1.04      1.14        2,249     0.99      0.61    989       \<0.001
  Plaque score (mm)             2.18      3.10        2,249     1.10      2.12    989       \<0.001
                                ***n***   **%**       ***N***   ***n***   **%**   ***N***   ***P***
  Smoking                       60        4.7         1,273     0         0.0     515       \<0.001
  Drinking                      68        5.3         1,205     1         0.2     514       \<0.001
  Carotid plaque                1,115     49.6        2,249     315       31.9    989       \<0.001
  Plaque at CCA                 1,047     46.6        2,249     287       29.0    989       \<0.001
  Plaque at ICA                 320       14.2        2,249     64        6.5     989       \<0.001
  Plaque at ECA                 84        3.7         2,249     14        1.4     989       \<0.001
  **Carotid plaque**                                                                        \<0.001
  **composition**                                                                           
   None                         1,134     50.4        2,249     674       68.1    989       
   Echolucent                   440       19.6        2,249     125       12.6    989       
   Echogenic                    13        0.6         2,249     10        1.0     989       
   Heterogeneous                307       13.7        2,249     106       10.7    989       
   Polytype                     355       15.8        2,249     74        7.5     989       
  **Count of carotid plaque**                                                               \<0.001
   0                            1,134     50.0        2,249     674       68.1    989       
   1                            441       19.6        2,249     159       16.1    989       
   2                            279       12.4        2,249     83        8.4     989       
   ≥3                           394       17.5        2,249     72        7.3     989       

Plaque score is the sum of all the plaque thickness measurements. Carotid plaque composition: if all the plaques in a subject had the same composition, the subject was classified according to that composition; if the plaque had different composition, the subject was classified as having polytype plaques.

*BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; WBC, white blood cell; MICPT, maximal internal carotid plaque thickness; CCA, common carotid artery; ICA, internal carotid artery; ECA, external carotid artery*.

WBC and the Presence of CAPs
----------------------------

In men, the total WBC, neutrophil, and monocyte counts showed significant positive correlations with the presence of CAPs after adjustment for age, BMI, SBP, DBP, TC, TG, HDLc, LDLc, fasting glucose, and uric acid (*P* \< 0.001, *P*~trend~ \< 0.001; [Table 2](#T2){ref-type="table"}). In women, the total WBC and differential WBC counts showed no significant association with the presence of CAPs ([Table 3](#T3){ref-type="table"}). The associations of the total WBC, neutrophil, and monocyte counts with the presence of CAPs existed even after further adjustment for smoking and drinking. The odds ratios (95% CI) of the individuals with CAP in the highest (compared to the lowest) quartile were 1.99 (1.33--2.97), 1.65 (1.10--2.47), and 2.17 (1.41--3.18) (*P*~trend~ = 0.004, *P*~trend~ = 0.004, and *P*~trend~ \< 0.001, respectively) for the total WBC, neutrophil, and monocytes count, respectively. Similar, but less robust, results were found for the percentages of neutrophils, lymphocytes, and basophils (*P* \< 0.05, *P*~trend~ \< 0.05). Further analysis revealed that the significant associations of the total WBC, neutrophil, and monocyte counts with the presence of CAPs only existed in men aged 45--65 years ([Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). Additionally, restrictive cubic spline showed that the total WBC, neutrophil, and monocyte counts had a non-linear relationship with the presence of CAPs, consistent with the main results ([Figures S2--S4](#SM1){ref-type="supplementary-material"}).

###### 

Odds ratios and 95% CI for carotid artery plaque by quartiles of the total white blood cell (WBC) and differential WBC counts for men.

                                            **Odds ratios (95% CI) for carotid plaque**                                                                                                                                                                            
  ----------------------------------------- --------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- -------------
  **Total WBC count (× 10**^**9**^**/L)**                                                                                                                                                                                                                          
   Cases, *N*                               472                                           485                                                    504                                                      475                                                      
   Model 1                                  1.00                                          1.30 (0.98--1.73)                                      1.22 (0.92--1.62)                                        2.06 (1.54--2.76)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 2                                  1.00                                          1.31 (0.96--1.80)                                      1.21 (0.89--1.65)                                        2.07 (1.50--2.85)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 3                                  1.00                                          1.56 (1.05--2.31)[^\*^](#TN1){ref-type="table-fn"}     1.36 (0.92--2.02)                                        1.99 (1.33--2.97)[^\*\*^](#TN2){ref-type="table-fn"}     **0.004**
  **Neutrophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                              
   Cases, *N*                               456                                           517                                                    481                                                      493                                                      
   Model 1                                  1.00                                          1.39 (0.99--1.76)                                      1.60 (1.20--2.14)[^\*\*^](#TN2){ref-type="table-fn"}     1.99 (1.49--2.66)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 2                                  1.00                                          1.38 (1.01--1.89)[^\*^](#TN1){ref-type="table-fn"}     1.76 (1.28--2.42)[^\*\*\*^](#TN3){ref-type="table-fn"}   2.10 (1.52--2.89)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 3                                  1.00                                          1.39 (0.95--2.06)                                      1.97 (1.33--2.93)[^\*\*^](#TN2){ref-type="table-fn"}     1.65 (1.10--2.47)[^\*^](#TN1){ref-type="table-fn"}       **0.004**
  **Neutrophils (%)**                                                                                                                                                                                                                                              
   Cases, *N*                               481                                           493                                                    498                                                      473                                                      
   Model 1                                  1.00                                          1.53 (1.15--2.03)[^\*\*^](#TN2){ref-type="table-fn"}   1.46 (1.10--1.93)[^\*\*^](#TN2){ref-type="table-fn"}     1.36 (1.02--1.81)[^\*^](#TN1){ref-type="table-fn"}       0.063
   Model 2                                  1.00                                          1.50 (1.11--2.04)[^\*\*^](#TN2){ref-type="table-fn"}   1.65 (1.21--2.24)[^\*\*^](#TN2){ref-type="table-fn"}     1.38 (1.01--1.89)[^\*^](#TN1){ref-type="table-fn"}       **0.031**
   Model 3                                  1.00                                          1.26 (0.86--1.83)                                      1.58 (1.08--2.31)[^\*^](#TN1){ref-type="table-fn"}       0.97 (0.64--1.45)                                        0.696
  **Lymphocytes (× 10**^**9**^**/L)**                                                                                                                                                                                                                              
   Cases, *N*                               525                                           424                                                    494                                                      504                                                      
   Model 1                                  1.00                                          1.00 (0.75--1.33)                                      1.05 (0.79--1.38)                                        1.48 (1.12--1.95)[^\*\*^](#TN2){ref-type="table-fn"}     **0.007**
   Model 2                                  1.00                                          0.91 (0.66--1.25)                                      1.05 (0.77--1.42)                                        1.36 (1.00--1.85)[^\*^](#TN1){ref-type="table-fn"}       **0.033**
   Model 3                                  1.00                                          0.88 (0.59--1.32)                                      0.98 (0.65--1.40)                                        1.41 (0.96--2.08)                                        0.076
  **Lymphocytes (%)**                                                                                                                                                                                                                                              
   Cases, *N*                               473                                           500                                                    468                                                      480                                                      
   Model 1                                  1.00                                          1.06 (0.80--1.40)                                      0.94 (0.71--1.25)                                        0.84 (0.63--1.12)                                        0.155
   Model 2                                  1.00                                          1.04 (0.76--1.42)                                      0.94 (0.68--1.28)                                        0.75 (0.54--1.02)                                        **0.047**
   Model 3                                  1.00                                          1.39 (0.93--2.06)                                      1.04 (0.69--1.56)                                        1.09 (0.72--1.63)                                        0.837
  **Monocytes (× 10**^**9**^**/L)**                                                                                                                                                                                                                                
   Cases, *N*                               485                                           507                                                    484                                                      467                                                      
   Model 1                                  1.00                                          1.22 (0.93--1.62)                                      1.20 (0.90--1.59)                                        2.19 (1.64--2.93)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 2                                  1.00                                          1.24 (0.91--1.68)                                      1.26 (0.92--1.72)                                        2.14 (1.56--2.94)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
   Model 3                                  1.00                                          1.46 (0.99--2.17)                                      1.69 (1.13--2.47)[^\*^](#TN1){ref-type="table-fn"}       2.17 (1.41--3.18)[^\*\*\*^](#TN3){ref-type="table-fn"}   **\<0.001**
  **Monocytes (%)**                                                                                                                                                                                                                                                
   Cases, *N*                               479                                           493                                                    498                                                      475                                                      
   Model 1                                  1.00                                          1.13 (0.85--1.49)                                      1.15 (0.87--1.52)                                        1.13 (0.85--1.50)                                        0.418
   Model 2                                  1.00                                          1.10 (0.81--1.49)                                      1.17 (0.86--1.59)                                        1.14 (0.84--1.56)                                        0.367
   Model 3                                  1.00                                          1.07 (0.73--1.57)                                      1.18 (0.80--1.76)                                        1.28 (0.87--1.89)                                        0.179
  **Eosinophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                              
   Cases, *N*                               531                                           448                                                    470                                                      497                                                      
   Model 1                                  1.00                                          1.23 (0.96--1.62)                                      1.29 (0.97--1.70)                                        1.31 (1.00--1.73)                                        **0.049**
   Model 2                                  1.00                                          1.29 (0.94--1.75)                                      1.27 (0.93--1.73)                                        1.35 (0.99--1.82)                                        0.071
   Model 3                                  1.00                                          1.51 (1.02--2.23)[^\*^](#TN1){ref-type="table-fn"}     1.55 (1.05--2.28)[^\*^](#TN1){ref-type="table-fn"}       1.28 (0.88--1.88)                                        0.200
  **Eosinophils (%)**                                                                                                                                                                                                                                              
   Cases, *N*                               475                                           479                                                    504                                                      489                                                      
   Model 1                                  1.00                                          0.81 (0.61--1.08)                                      1.00 (0.78--1.32)                                        0.89 (0.67--1.18)                                        0.767
   Model 2                                  1.00                                          0.81 (0.60--1.10)                                      0.95 (0.70--1.28)                                        0.86 (0.63--1.17)                                        0.543
   Model 3                                  1.00                                          0.92 (0.62--1.35)                                      1.33 (0.91--1.95)                                        1.07 (0.73--1.57)                                        0.359
  **Basophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                                
   Cases, *N*                               556                                           566                                                    389                                                      434                                                      
   Model 1                                  1.00                                          1.17 (0.90--1.53)                                      1.35 (1.01--1.81)[^\*^](#TN1){ref-type="table-fn"}       1.42 (1.07--1.89)[^\*^](#TN1){ref-type="table-fn"}       **0.009**
   Model 2                                  1.00                                          1.16 (0.88--1.54)                                      1.45 (1.05--1.99)[^\*^](#TN1){ref-type="table-fn"}       1.46 (1.07--2.00)[^\*^](#TN1){ref-type="table-fn"}       **0.007**
   Model 3                                  1.00                                          1.01 (0.70--1.44)                                      1.21 (0.81--1.82)                                        1.45 (0.99--2.13)                                        **0.039**
  **Basophils (%)**                                                                                                                                                                                                                                                
   Cases, *N*                               333                                           470                                                    752                                                      392                                                      
   Model 1                                  1.00                                          0.91 (0.66--1.24)                                      1.01 (0.75--1.34)                                        0.99 (0.71--1.37)                                        0.806
   Model 2                                  1.00                                          0.88 (0.62--1.24)                                      1.01 (0.73--1.38)                                        1.06 (0.74--1.51)                                        0.515
   Model 3                                  1.00                                          0.92 (0.59--1.43)                                      0.86 (0.57--1.30)                                        1.14 (0.72--1.81)                                        0.648

Model 1 was adjusted for age and BMI.

Model 2 included additional adjustments for systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and uric acid.

Model 3 included additional adjustments for drinking and smoking.

P ≤ 0.05,

P ≤ 0.01, and

*P ≤ 0.001 compared with Q1 (Bonferroni). Bold P indicates statistical significance*.

###### 

Odds ratios and 95% CI for carotid artery plaque by quartiles of total white blood cell (WBC) and differential WBC counts for women.

                                            **Odds ratios (95% CI) for carotid plaque**                                                               
  ----------------------------------------- --------------------------------------------- ------------------- ------------------- ------------------- -------
  **Total WBC count (× 10**^**9**^**/L)**                                                                                                             
   Cases, *N*                               219                                           184                 223                 196                 
   Model 1                                  1.00                                          1.20 (0.74--1.97)   1.32 (0.83--2.11)   1.06 (0.65--1.75)   0.677
   Model 2                                  1.00                                          1.12 (0.65--1.98)   1.12 (0.67--1.88)   0.95 (0.55--1.64)   0.879
  **Neutrophils (× 10**^**9**^**/L)**                                                                                                                 
   Cases, *N*                               224                                           214                 182                 204                 
   Model 1                                  1.00                                          1.69 (1.05--2.70)   1.35 (0.82--2.23)   1.60 (0.98--2.62)   0.125
   Model 2                                  1.00                                          1.49 (0.89--2.50)   1.20 (0.69--2.09)   1.43 (0.83--2.45)   0.337
  **Neutrophils (%)**                                                                                                                                 
   Cases, *N*                               208                                           208                 206                 201                 
   Model 1                                  1.00                                          1.13 (0.70--1.82)   0.98 (0.60--1.59)   1.60 (0.99--2.61)   0.114
   Model 2                                  1.00                                          1.12 (0.66--1.88)   0.97 (0.57--1.65)   1.55 (0.91--2.66)   0.190
  **Lymphocytes (× 10**^**9**^**/L)**                                                                                                                 
   Cases, *N*                               227                                           211                 200                 185                 
   Model 1                                  1.00                                          0.75 (0.46--1.21)   0.92 (0.57--1.46)   0.81 (0.50--1.32)   0.567
   Model 2                                  1.00                                          0.79 (0.47--1.33)   0.72 (0.43--1.20)   0.74 (0.43--1.28)   0.239
  **Lymphocytes (%)**                                                                                                                                 
   Cases, *N*                               193                                           213                 204                 206                 
   Model 1                                  1.00                                          0.79 (0.49--1.29)   0.72 (0.44--1.18)   0.67 (0.41--1.10)   0.114
   Model 2                                  1.00                                          0.66 (0.38--1.13)   0.68 (0.40--1.16)   0.66 (0.38--1.12)   0.160
  **Monocytes (× 10**^**9**^**/L)**                                                                                                                   
   Cases, *N*                               114                                           307                 214                 188                 
   Model 1                                  1.00                                          1.62 (0.93--2.81)   1.18 (0.65--2.13)   1.41 (0.77--2.58)   0.802
   Model 2                                  1.00                                          1.37 (0.74--2.54)   1.01 (0.53--1.95)   1.36 (0.71--2.63)   0.746
  **Monocytes (%)**                                                                                                                                   
   Cases, *N*                               210                                           211                 193                 210                 
   Model 1                                  1.00                                          1.02 (0.64--1.64)   0.83 (0.51--1.35)   0.87 (0.54--1.40)   0.417
   Model 2                                  1.00                                          1.09 (0.65--1.84)   0.87 (0.50--1.49)   0.98 (0.58--1.65)   0.749
  **Eosinophils (× 10**^**9**^**/L)**                                                                                                                 
   Cases, *N*                               211                                           203                 214                 195                 
   Model 1                                  1.00                                          1.00 (0.61--1.62)   1.04 (0.64--1.68)   0.71 (0.43--1.18)   0.247
   Model 2                                  1.00                                          0.73 (0.42--1.28)   1.03 (0.60--1.76)   0.67 (0.38--1.18)   0.366
  **Eosinophils (%)**                                                                                                                                 
   Cases, *N*                               206                                           200                 215                 203                 
   Model 1                                  1.00                                          1.33 (0.82--2.16)   0.94 (0.58--1.53)   0.84 (0.51--1.38)   0.275
   Model 2                                  1.00                                          1.05 (0.62--1.80)   0.81 (0.48--1.39)   0.81 (0.47--1.38)   0.293
  **Basophils (× 10**^**9**^**/L)**                                                                                                                   
   Cases, *N*                               271                                           266                 138                 149                 
   Model 1                                  1.00                                          0.79 (0.52--1.19)   0.70 (0.42--1.16)   0.68 (0.41--1.13)   0.091
   Model 2                                  1.00                                          0.74 (0.47--1.18)   0.68 (0.39--1.17)   0.73 (0.41--1.29)   0.165
  **Basophils (%)**                                                                                                                                   
   Cases, *N*                               128                                           368                 146                 182                 
   Model 1                                  1.00                                          1.24 (0.76--2.03)   0.74 (0.40--1.35)   0.82 (0.46--1.44)   0.116
   Model 2                                  1.00                                          1.36 (0.79--2.33)   0.78 (0.40--1.50)   0.97 (0.52--1.81)   0.345

Model 1 was adjusted for age and BMI.

*Model 2 included additional adjustments for systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and uric acid*.

###### 

Adjusted odds ratios and 95% CI for carotid artery plaque stratified by age for men.

                                            **Adjusted odds ratios (95% CI) for carotid plaque**                                                                                                                                                                            
  ----------------------------------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------- -------------
  **Total WBC count (× 10**^**9**^**/L)**                                                                                                                                                                                                                                   
   \<45 years                               1.00                                                   1.50 (0.64--3.53)                                       1.64 (0.72--3.70)                                      1.85 (0.83--4.10)                                         0.170
   45--65 years                             1.00                                                   1.16 (0.81--1.65)                                       1.11 (0.78--1.58)                                      1.82 (1.28--2.59)[^\*\*\*^](#TN6){ref-type="table-fn"}    **\<0.001**
   ≥65 years                                1.00                                                   1.80 (0.46--7.09)                                       0.70 (0.18--2.71)                                      1.74 (0.44--6.92)                                         0.479
   *P*~interaction~                         0.807                                                                                                                                                                                                                           
  **Neutrophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                                       
   \<45 years                               1.00                                                   2.44 (0.96--6.20)                                       2.96 (1.17--7.48)[^\*^](#TN4){ref-type="table-fn"}     3.18 (1.26--8.03)[^\*^](#TN4){ref-type="table-fn"}        0.071
   45--65 years                             1.00                                                   1.26 (0.88--1.81)                                       1.59 (1.12--2.25)[^\*\*^](#TN5){ref-type="table-fn"}   1.93 (1.35--2.78)[^\*\*\*^](#TN6){ref-type="table-fn"}    **0.012**
   ≥65 years                                1.00                                                   1.32 (0.35--5.02)                                       3.46 (0.73--16.41)                                     1.55 (0.41--5.93)                                         0.218
   *P*~interaction~                         0.333                                                                                                                                                                                                                           
  **Lymphocytes (× 10**^**9**^**/L)**                                                                                                                                                                                                                                       
   \<45 years                               1.00                                                   0.90 (0.39--2.08)                                       0.65 (0.28--1.53)                                      1.15 (0.52--2.55)                                         0.725
   45--65 years                             1.00                                                   0.99 (0.69--1.41)                                       1.12 (0.78--1.62)                                      1.41 (0.98--2.05)                                         **0.047**
   ≥65 years                                1.00                                                   0.57 (0.16--2.07)                                       1.22 (0.25--5.85)                                      0.58 (0.15--2.34)                                         0.274
   *P*~interaction~                         0.426                                                                                                                                                                                                                           
  **Monocytes (× 10**^**9**^**/L)**                                                                                                                                                                                                                                         
   \<45 years                               1.00                                                   1.60 (0.76--3.36)                                       0.87 (0.41--1.85)                                      1.31 (0.62--2.77)                                         0.770
   45--65 years                             1.00                                                   1.15 (0.82--1.62)                                       1.56 (1.09--2.23)[^\*^](#TN4){ref-type="table-fn"}     2.29 (1.59--3.30)[^\*\*\*^](#TN6){ref-type="table-fn"}    **\<0.001**
   ≥65 years                                1.00                                                   3.29 (0.78--13.78)                                      0.99 (0.28--3.49)                                      24.40 (2.48--239.75)[^\*\*^](#TN5){ref-type="table-fn"}   0.104
   *P*~interaction~                         0.341                                                                                                                                                                                                                           
  **Eosinophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                                       
   \<45 years                               1.00                                                   1.63 (0.75--3.52)                                       1.70 (0.80--3.60)                                      1.28 (0.58--2.81)                                         0.602
   45--65 years                             1.00                                                   1.06 (0.73--1.53)                                       1.16 (0.82--1.64)                                      1.23 (0.87--1.75)                                         0.584
   ≥65 years                                1.00                                                   2.53 (0.66--9.67)                                       2.41 (0.68--8.51)                                      7.13 (1.61--31.64)                                        0.394
   *P*~interaction~                         0.911                                                                                                                                                                                                                           
  **Basophils (× 10**^**9**^**/L)**                                                                                                                                                                                                                                         
   \<45 years                               1.00                                                   1.56 (0.77--3.15)                                       1.44 (0.68--3.07)                                      1.01 (0.47--2.17)                                         0.711
   45--65 years                             1.00                                                   1.01 (0.74--1.37)                                       1.47 (1.03--2.08)[^\*^](#TN4){ref-type="table-fn"}     1.63 (1.14--2.32)[^\*\*^](#TN5){ref-type="table-fn"}      0.921
   ≥65 years                                1.00                                                   10.94 (1.19--100.27)[^\*^](#TN4){ref-type="table-fn"}   2.02 (0.51--8.01)                                      2.09 (0.67--6.54)                                         0.675
   *P*~interaction~                         0.884                                                                                                                                                                                                                           

Model adjusted for BMI, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and uric acid.

WBC, white blood cell.

P ≤ 0.05,

P ≤ 0.01, and

*P ≤ 0.001 compared with Q1 (Bonferroni). Bold P indicates statistical significance*.

###### 

Adjusted odds ratios and 95% CI for carotid artery plaque stratified by age for women.

                                            **Adjusted odds ratios (95% CI) for carotid plaque**                                                                                                                                  
  ----------------------------------------- ------------------------------------------------------ ---------------------------------------------------- ----------------------------------------------------- ------------------- -------
  **Total WBC count (× 10**^**9**^**/L)**                                                                                                                                                                                         
   \<45 years                               1.00                                                   0.15 (0.01--1.76)                                    0.88 (0.16--5.00)                                     0.16 (0.01--2.07)   0.263
   45--65 years                             1.00                                                   1.02 (0.60--1.72)                                    1.05 (0.60--1.85)                                     0.89 (0.46--1.73)   0.656
   ≥65 years                                1.00                                                   0.81 (0.19--3.42)                                    0.87 (0.16--4.63)                                     0.39 (0.09--1.65)   0.206
   *P*~interaction~                         0.111                                                                                                                                                                                 
  **Neutrophils (× 10**^**9**^**/L)**                                                                                                                                                                                             
   \<45 years                               1.00                                                   1.19 (0.19--7.30)                                    1.23 (0.20--7.40)                                     0.18 (0.01--2.37)   0.149
   45--65 years                             1.00                                                   1.23 (0.71--2.12)                                    1.30 (0.72--2.37)                                     1.94 (1.02--2.67)   0.510
   ≥65 years                                1.00                                                   0.64 (0.15--2.75)                                    0.80 (0.15--4.24)                                     0.27 (0.06--1.18)   0.366
   *P*~interaction~                         0.168                                                                                                                                                                                 
  **Lymphocytes (× 10**^**9**^**/L)**                                                                                                                                                                                             
   \<45 years                               1.00                                                   0.35 (0.05--2.50)                                    2.27 (0.40--2.51)                                     0.54 (0.05--2.51)   0.757
   45--65 years                             1.00                                                   0.76 (0.44--1.30)                                    0.71 (0.39--1.29)                                     0.98 (0.52--1.83)   0.440
   ≥65 years                                1.00                                                   1.31 (0.26--6.61)                                    0.66 (0.14--2.99)                                     0.51 (0.11--2.29)   0.520
   *P*~interaction~                         0.471                                                                                                                                                                                 
  **Monocytes (× 10**^**9**^**/L)**                                                                                                                                                                                               
   \<45 years                               1.00                                                   2.20 (0.34--14.47)                                   8.26 (1.28--53.25)[^\*^](#TN7){ref-type="table-fn"}   --                  0.921
   45--65 years                             1.00                                                   0.83 (0.50--1.36)                                    1.12 (0.62--2.04)                                     0.85 (0.38--1.92)   0.703
   ≥65 years                                1.00                                                   0.56 (0.15--2.07)                                    0.73 (0.14--3.86)                                     0.26 (0.04--1.63)   0.164
   *P*~interaction~                         0.235                                                                                                                                                                                 
  **Eosinophils (× 10**^**9**^**/L)**                                                                                                                                                                                             
   \<45 years                               1.00                                                   0.52 (0.08--3.39)                                    1.22 (0.22--6.63)                                     --                  0.378
   45--65 years                             1.00                                                   1.02 (0.57--1.81)                                    1.43 (0.81--2.53)                                     1.02 (0.54--1.93)   0.728
   ≥65 years                                1.00                                                   0.48 (0.09--2.71)                                    0.50 (0.09--2.85)                                     0.90 (0.15--5.53)   0.314
   *P*~interaction~                         0.066                                                                                                                                                                                 
  **Basophils (× 10**^**9**^**/L)**                                                                                                                                                                                               
   \<45 years                               1.00                                                   0.52 (0.09--2.91)                                    0.26 (0.02--2.94)                                     0.67 (0.10--2.91)   0.626
   45--65 years                             1.00                                                   0.88 (0.53--1.46)                                    0.82 (0.45--1.51)                                     0.73 (0.38--1.41)   0.308
   ≥65 years                                1.00                                                   0.14 (0.03--0.75)[^\*^](#TN7){ref-type="table-fn"}   0.16 (0.03--0.93)[^\*^](#TN7){ref-type="table-fn"}    0.22 (0.04--1.26)   0.470
   *P*~interaction~                         0.435                                                                                                                                                                                 

Model adjusted for BMI, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and uric acid.

WBC, white blood cell.

*P ≤ 0.05 compared with Q1 (Bonferroni)*.

WBCs and the Severity of CAPs
-----------------------------

In the total study population, the total WBC, neutrophil, and monocyte counts were significantly correlated with the severity of carotid atherosclerosis, as judged by either the sum of CAPs, MICPT, or the plaque score (all *P* \< 0.01, *P*~trend~ \< 0.05; [Tables S1](#SM1){ref-type="supplementary-material"}--[S3](#SM1){ref-type="supplementary-material"}). Similar results were found for the percentage of lymphocytes (*P* \< 0.05).

WBCs and the Types of CAPs
--------------------------

Significant differences were observed between participants without CAPs and participants with different subtypes of CAPs ([Table S4](#SM1){ref-type="supplementary-material"}). Compared with the participants without CAPs, those with echolucent plaques showed significantly increased total WBC and neutrophil counts, but significantly decreased percentage of lymphocytes, whereas those with polytype plaques showed significantly increased monocyte counts.

Discussion {#s4}
==========

To our knowledge, the current study is the first to investigate the associations of the total WBC and WBC subtype counts with the presence, severity, and subtypes of CAPs in a healthy Chinese population. Our results suggest that the total WBC and WBC subtype counts contain important risk information for CAPs. The total WBC, neutrophil, and monocyte counts were significantly associated with increased odds of the presence of CAPs in men, but not in women after adjustment for potential confounding factors. These three counts also showed significant positive associations with the severity and subtypes of CAPs.

Several epidemiologic observational studies have reported that an increased WBC count is associated with a higher cardiovascular risk prediction ([@B8], [@B9]). The total WBC and neutrophil counts are also confirmed as risk factors for the outcomes of myocardial infarction and cerebral infarction ([@B16], [@B17]) and are associated with infarction size ([@B18]). Interestingly, the neutrophil count has been found to be significantly associated with the angiographic characteristics of coronary artery disease, strongly suggesting that neutrophil was involved in the development of coronary atherosclerosis ([@B19]). The results of our study not only confirm the positive relationship between the total WBC count and CAPs but also show that neutrophils and monocytes are superior to other WBC subtypes in indicating the presence of CAPs.

Gender differences in the prevalence and complications of atherosclerosis are well-known. However, data are limited in the clinical and preclinical literature to provide robust evidence regarding the underlying mechanisms. Genetic background and biological heterogeneity might play essential roles in the gender difference observed in atherosclerosis ([@B20]). Moreover, the influence of sex hormones on atherosclerosis is still controversial ([@B21]). Research indicates that although younger women have a lower risk of cardiovascular disease than men, women\'s risk catches up to and even surpasses that of men at the age of 60--79 years ([@B22]). Moreover, the risk factors for atherosclerosis might differ between genders. In our study, the overall BMI, blood pressure, and lipid profiles were significantly lower in women, which might have contributed to the differential results in the association between leukocytes and CAPs.

Studies have shown that CAP burden might be an independent indicator of the severity of intracranial artery atherosclerosis and can also predict future cardiovascular and cerebrovascular events ([@B23]). Hence, CAP burden may be more meaningful than just the presence or absence of a carotid plaque. A study among Hispanics found that individuals in the highest quartile of the WBC count had significantly increased MICPT compared with the subjects in the lowest quartile ([@B13]). Another study in non-smoking men (*n* = 571) found that the presence and severity of carotid atherosclerosis were significantly associated with increased counts of total WBCs, neutrophils, and monocytes ([@B24]). These results are consistent with our finding that the total WBC, neutrophil, and monocyte counts were significantly positively correlated with the sum of CAPs, MICPT, and the plaque score.

The risk of rupture of atherosclerotic plaques is a main concern in carotid atherosclerosis. Generally, the stability of CAP could be indicated by its compositions. Echolucent or hypoechogenic plaques were mainly composed of lipids, inflammatory cells, and neovessels. However, echogenic plaques mainly comprise calcified tissues ([@B25]). Previous studies have found that compared to echogenic plaques, echolucent plaques are associated with cerebrovascular events and future coronary events ([@B26]). The leukocyte count has been reported to be associated with the degree of CAP instability ([@B27]), and a high neutrophil count in CAPs is related to the features of rupture-prone lesions ([@B28]). In our study, we also found that, compared with the participants without CAP, those with echolucent plaques showed significantly increased total WBC and neutrophils counts, whereas those with polytype plaques showed significantly increased monocyte counts.

Several pathophysiological mechanisms potentially link the WBCs and WBC subtypes to plaque formation and vulnerability. First of all, recruitment of leukocytes to the vessel endothelium wall represents an early stage in the development of atherosclerosis. CAP is characterized by the infiltration of inflammatory cells, which transmigrated from blood into the subendothelial layers of the arteries ([@B29]). Monocytes are the primary inflammatory infiltrating cells in early atherosclerotic plaques, and their accumulation increased proportionally with plaque size ([@B30]). The presence of neutrophil invasion in atherosclerotic plaques has been shown in an animal model and in patients with acute coronary syndrome ([@B31]). Neutrophils localized in rupture-prone areas and released active mediators, which caused plaque instability ([@B28]). Secondly, inflammation cells play a vital role in the progress of atherosclerosis and plaque vulnerability ([@B32]). Monocytes, as representatives of the innate immune system, could drive the progression of atherosclerosis from a stable to an unstable state ([@B33], [@B34]). Neutrophils also promoted the progression of atherosclerosis because of their ability to activate other immune cells, especially monocytes, instructing them to directly participate in the inflammation, and/or release pro-inflammatory mediators. Furthermore, neutrophils might increase plaque vulnerability by releasing various enzymes, including gelatinase, collagenase, myeloperoxidase, and elastase ([@B35]).

This study has some limitations to acknowledge. Firstly, it was designed as a cross-sectional observational study, so no causal relationship can be drawn. Our results should be further investigated in a large prospective cohort. Secondly, the cross-sectional design may lead to a selection bias, especially with respect to the healthy elderly. However, excluding subjects with histories of cardiovascular diseases might partially decrease the bias. Thirdly, the study population was less likely to be smokers than the general Chinese population. Therefore, caution should be exercised when generalizing the results. Finally, the assessment of CAP with ultrasound may be less reliable than with magnetic resonance imaging or computed tomography. However, considering its convenience and the likelihood of technical improvements, ultrasound still remains the first choice for CAP assessment.

In conclusion, this study found that the total WBC, neutrophil, and monocyte counts are associated with the presence, severity, and types of CAPs in healthy Chinese adults, and these markers may be useful in clinical practice.
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